[go: up one dir, main page]

HUP0000553A1 - Hattagú, nitrogéntartalmú heteroaromás karbonsavszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására - Google Patents

Hattagú, nitrogéntartalmú heteroaromás karbonsavszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására

Info

Publication number
HUP0000553A1
HUP0000553A1 HU0000553A HUP0000553A HUP0000553A1 HU P0000553 A1 HUP0000553 A1 HU P0000553A1 HU 0000553 A HU0000553 A HU 0000553A HU P0000553 A HUP0000553 A HU P0000553A HU P0000553 A1 HUP0000553 A1 HU P0000553A1
Authority
HU
Hungary
Prior art keywords
group
optionally substituted
general formula
atom
pharmaceutical compositions
Prior art date
Application number
HU0000553A
Other languages
English (en)
Inventor
Wilhelm Amberg
Stefan Hergenröder
Rolf Jansen
Andreas Kling
Dagmar Klinge
Manfred Raschack
Hartmut Riechers
Liliane Unger
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996152763 external-priority patent/DE19652763A1/de
Priority claimed from DE1997100884 external-priority patent/DE19700884A1/de
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of HUP0000553A1 publication Critical patent/HUP0000553A1/hu
Publication of HUP0000553A3 publication Critical patent/HUP0000553A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • C07D237/16Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C07D253/10Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát az új (I) általános képletű karbonsavszármazékok-, ahol R1 tetrazolil- vagy (a) általános képletű csoport; X nitrogénatom vagy metincsoport; Y nitrogénatom vagy CR9 általános képletű csoport; Z nitrogénatom vagy CR10 általános képletű csoport; R2 adott esetben szubsztituált alkil-, alkenil- vagy alkinilcsoport,hidrogén-, halogénatom, alkoxi-, halogén-alkoxi-, alkenil-oxi-,alkinil-oxi-, alkil-tio-, alkil-karbonil-, alkoxi-karbonil-csoport,mono- vagy dialkil-amino-csoport, hidroxi-, karboxi-, aminocsoport;vagy CR2 CR9-cel vagy CR10-zel együtt 5 vagy 6 tagú, adott esetbenszubsztituált alkilén- vagy alkeniléngyűrűt alkot; R3 és R4 azonosak vagy különbözők, és jelentésük adott esetbenszubsztituált fenil- vagy naftilcsoportok, vagy fenil- vagynaftilcsoportok, amelyek orto-helyzetben közvetlenül egy metilén-,etilén- vagy eteniléncsoporton, illetve oxigén- vagy szénatomon, vagySO2-, NH- vagy N-alkil-csoporton keresztül egymássalösszekapcsolódnak, adott esetben szubsztituált cikloalkilcsoportok; R5 hidrogénatom, adott esetben szubsztituált alkil-, alkenil- vagyalkinilcsoport, adott esetben szubsztituált fenil- vagy naftil-, öt-vagy hattagú heteroaromás vagy cikloalkilcsoport; R9 és R10 azonosak vagy különbözők, és jelentésük hidrogénatom,hidroxi-, amino-, mono- vagy dialkil-amino-csoport, halogénatom,alkoxi-, halogén-alkoxi- vagy alkil-tio-csoport, adott esetbenszubsztituált alkil-, alkenil-, alkinilcsoport, vagy CR9 vagy CR10CR2-vel együtt 5 vagy 6 tagú gyűrűt alkot; W kén-, oxigénatom vagy kémiai kötést kifejező vegyértékvonal; Q oxigén- vagy nitrogénatom -, valamint gyógyszerkészítményekelőállítására történő alkalmazásuk képezi. Az (I) általános képletűvegyületek endotelinreceptor-antagonista hatásúak, így többek közöttkrónikus szívelégtelenség, magas vérnyomás, akut/krónikusveseelégtelenség kezelésére alkalmazhatóak. (a) Ó
HU0000553A 1996-12-18 1997-12-04 Sixmembered nitrogencontained heteroaromatic carboxylic acid derivatives, pharmaceutical compositions containing them, and their use for producing pharmaceutical compositions HUP0000553A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1996152763 DE19652763A1 (de) 1996-12-18 1996-12-18 Heterozyklische Carbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE1997100884 DE19700884A1 (de) 1997-01-13 1997-01-13 Heterozyklische Carbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
PCT/EP1997/006778 WO1998027070A1 (de) 1996-12-18 1997-12-04 Heterozyklische carbonsäurederivate, ihre herstellung und verwendung als endothelinrezeptorantagonisten

Publications (2)

Publication Number Publication Date
HUP0000553A1 true HUP0000553A1 (hu) 2001-04-28
HUP0000553A3 HUP0000553A3 (en) 2001-08-28

Family

ID=26032394

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000553A HUP0000553A3 (en) 1996-12-18 1997-12-04 Sixmembered nitrogencontained heteroaromatic carboxylic acid derivatives, pharmaceutical compositions containing them, and their use for producing pharmaceutical compositions

Country Status (21)

Country Link
US (1) US6448248B1 (hu)
EP (1) EP0946524A1 (hu)
JP (1) JP2001506243A (hu)
KR (1) KR20000057642A (hu)
CN (1) CN1247533A (hu)
AR (1) AR010359A1 (hu)
AU (1) AU740351B2 (hu)
BG (1) BG103502A (hu)
BR (1) BR9714047A (hu)
CA (1) CA2275256A1 (hu)
CO (1) CO4930270A1 (hu)
HR (1) HRP970686A2 (hu)
HU (1) HUP0000553A3 (hu)
ID (1) ID26234A (hu)
IL (1) IL130251A0 (hu)
NO (1) NO313519B1 (hu)
NZ (1) NZ336157A (hu)
PL (1) PL334014A1 (hu)
SK (1) SK77799A3 (hu)
TR (1) TR199901416T2 (hu)
WO (1) WO1998027070A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299741B6 (cs) * 1997-09-26 2008-11-05 Abbott Gmbh & Co. Kg Kombinace endotelinového antagonisty a RAS inhibitoru a její použití, farmaceutický prostredek s jejím obsahem a zpusob výroby tohoto prostredku
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
HU0900792D0 (en) * 1997-10-17 2010-03-01 Ark Therapeutics Ltd Use of renin-angiotensin inhibitors
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
DE19858779A1 (de) * 1998-12-18 2000-06-21 Basf Ag Neue ß-Amido und ß-Sulfonamidocarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19924892A1 (de) * 1999-06-01 2000-12-07 Basf Ag Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
IL148841A0 (en) * 1999-10-06 2002-09-12 Basf Ag INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αvβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
WO2003006041A1 (fr) * 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671551B1 (fr) * 1991-01-15 1993-03-12 Adir Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
AU5659498A (en) 1998-07-15
BG103502A (en) 2000-07-31
KR20000057642A (ko) 2000-09-25
WO1998027070A1 (de) 1998-06-25
AU740351B2 (en) 2001-11-01
JP2001506243A (ja) 2001-05-15
SK77799A3 (en) 2000-02-14
AR010359A1 (es) 2000-06-07
EP0946524A1 (de) 1999-10-06
HRP970686A2 (en) 1998-10-31
NO992976L (no) 1999-06-17
CN1247533A (zh) 2000-03-15
CA2275256A1 (en) 1998-06-25
ID26234A (id) 2000-12-07
HUP0000553A3 (en) 2001-08-28
TR199901416T2 (xx) 1999-08-23
PL334014A1 (en) 2000-01-31
BR9714047A (pt) 2000-05-09
NO313519B1 (no) 2002-10-14
CO4930270A1 (es) 2000-06-27
NO992976D0 (no) 1999-06-17
IL130251A0 (en) 2000-06-01
NZ336157A (en) 2000-10-27
US6448248B1 (en) 2002-09-10

Similar Documents

Publication Publication Date Title
HUP0000553A1 (hu) Hattagú, nitrogéntartalmú heteroaromás karbonsavszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására
HUP9800535A1 (hu) Pirimidinszármazékok alkalmazása rák megelőzésére szolgáló gyógyászati készítmények előállítására
TW200603736A (en) Chemical compounds
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
NZ331741A (en) use of a quinazolin-4-one derivative having an (S)-configuration to treat dyskinesia associated with dopamine agonist therapy
YU104690A (sh) Supstituisani imidazo-kondenzovani 6-člani heterocikli kao antagonisti angiotenzina 2
ES2082875T3 (es) 3,5-di-terc-butil-4-hidroxifenilmetileno-derivados de tiazolidinonas, oxazolidinonas e imidazolidinonas 2-sustituidas utiles como agentes antiinflamatorios.
MX9708782A (es) Heterociclos de 5 anillos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4.
MY119623A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
GEP20074144B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
BG49275A3 (en) Method for preparing diazobicycloalkylchinolin carbonate acids
TR200402069T4 (tr) Difenilüre türevleri ve bunların alfa 2/5-HT2c antagonisti olarak kullanılması
DE69516540D1 (de) AMINO-IMIDAZO [4,5-c] CHINOLINE
HUP0004437A2 (hu) Raf kinázt gátló hatású, szimmetrikusan és aszimmetrikusan szubsztituált difenil-karbamid-származékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények
TR200000025T2 (tr) Azetidinilpropilpiperidin türevleri, ara bağlarıyla tacikinin antagonistleri olarak kullanımları.
FI980471A0 (fi) 1,3-substituoidut sykloalkeenit ja sykloalkaanit keskushermostoon vaikuttavina aineina
HUP0204354A2 (hu) Új heterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TR200401716T4 (tr) Yeni üç yerdeğiştirme gruplu fenil türevleri ve analogları
TR199901381A2 (xx) Diaza-spiro$3,5]nonan t�revleri.
TW429148B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
HUP0004590A2 (hu) Endotelin-antagonista imidazolszármazékokat és béta receptor blokkolókat tartalmazó kombinációs gyógyszerkészítmények
HUP9700983A2 (hu) 1,4-Diaril-2-fluor-2-butén-származékok, intermedierjeik, előállításuk és alkalmazásuk, valamint hatóanyagként ezeket a vegyületeket tartalmazó inszekticid és akaricid készítmények
HUP0101311A1 (hu) 3-Szubsztituált 3,4,5,7-tetrahidro-pirrolo[3',4':4,5]tieno[2,3-d]pirimidin-származékok, eljárás előállításukra és alkalmazásuk 5-HT antagonistákként
MX9705649A (es) Compuestos de fenilo substituidos como antagonistas de endotelinas.
SE9701682D0 (sv) Compounds